Bicycle Therapeutics annual operating margin
2017
2018
2019
2020
2021
2022
2023
2024
2025
Bicycle Therapeutics's operating margin was −340.38% for fiscal 2025.
View full Bicycle Therapeutics company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −340.38% | +254.58 pp |
| 2024 | 2024-12-31 | −594.96% | +109.17 pp |
| 2023 | 2023-12-31 | −704.13% | +102.43 pp |
| 2022 | 2022-12-31 | −806.56% | −245.58 pp |
| 2021 | 2021-12-31 | −560.98% | −60.89 pp |
| 2020 | 2020-12-31 | −500.10% | −309.54 pp |
| 2019 | 2019-12-31 | −190.56% | +114.18 pp |
| 2018 | 2018-12-31 | −304.74% | +482.30 pp |
| 2017 | 2017-12-31 | −787.04% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −8,673.93% | −5708.10 pp |
| Q1 2026 | 2026-03-31 | −7,382.41% | −6678.75 pp |
| Q4 2025 | 2025-12-31 | −51.52% | +1773.26 pp |
| Q3 2025 | 2025-09-30 | −558.64% | +1827.23 pp |
| Q2 2025 | 2025-06-30 | −2,965.82% | −2467.51 pp |
| Q1 2025 | 2025-03-31 | −703.66% | −541.26 pp |
| Q4 2024 | 2024-12-31 | −1,824.78% | −807.43 pp |
| Q3 2024 | 2024-09-30 | −2,385.87% | −1436.75 pp |
| Q2 2024 | 2024-06-30 | −498.31% | −120.05 pp |
| Q1 2024 | 2024-03-31 | −162.40% | +691.42 pp |
| Q4 2023 | 2023-12-31 | −1,017.35% | −6.02 pp |
| Q3 2023 | 2023-09-30 | −949.12% | +29.79 pp |
| Q2 2023 | 2023-06-30 | −378.27% | +245.31 pp |
| Q1 2023 | 2023-03-31 | −853.82% | −144.42 pp |
| Q4 2022 | 2022-12-31 | −1,011.33% | −533.40 pp |
| Q3 2022 | 2022-09-30 | −978.91% | −649.03 pp |
| Q2 2022 | 2022-06-30 | −623.57% | +344.33 pp |
| Q1 2022 | 2022-03-31 | −709.40% | +176.88 pp |
| Q4 2021 | 2021-12-31 | −477.94% | −34.62 pp |
| Q3 2021 | 2021-09-30 | −329.89% | −52.04 pp |
| Q2 2021 | 2021-06-30 | −967.90% | −166.94 pp |
| Q1 2021 | 2021-03-31 | −886.28% | +144.98 pp |
| Q4 2020 | 2020-12-31 | −443.32% | −353.11 pp |
| Q3 2020 | 2020-09-30 | −277.85% | +1392.02 pp |
| Q2 2020 | 2020-06-30 | −800.95% | −276.12 pp |
| Q1 2020 | 2020-03-31 | −1,031.27% | −979.67 pp |
| Q4 2019 | 2019-12-31 | −90.21% | +304.63 pp |
| Q3 2019 | 2019-09-30 | −1,669.87% | −1371.37 pp |
| Q2 2019 | 2019-06-30 | −524.84% | — |
| Q1 2019 | 2019-03-31 | −51.60% | — |
| Q3 2018 | 2018-09-30 | −394.84% | — |
| Q2 2018 | 2018-06-30 | −298.49% | — |
Over the last five reported fiscal years, Bicycle Therapeutics's operating margin increased from −500.10% to −340.38%, a change of +159.72 percentage points. The latest reported quarter, Q2 2026, shows −8,673.93%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Bicycle Therapeutics filings at SEC.gov ↗